NCT01471197 - Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Lung Cancer - Non Small Cell

Interventions

BIOLOGICAL

Ipilimumab

Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion

BIOLOGICAL

Pemetrexed

IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.

Trial Locations (13)

Local Institution, Bruges

Local Institution, Sint-Niklaas

Local Institution, Hamburg

Meritus Center For Clinical Research, Hagerstown

Blue Ridge Cancer Care, Christiansburg

Carolina Biooncology Institute, Huntersville

Montgomery Cancer Center, Mount Sterling

Medical And Surgical Specialists, Llc, Galesburg

Quincy Medical Group, Quincy

Local Institution, Heidelberg

Local Institution, Paris

Marin Specialty Care, Inc., Greenbrae

Local Institution, Benidorm-Alicante